Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

NCT00397904 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

BIOLOGICAL: cetuximab
DRUG: cisplatin
DRUG: irinotecan hydrochloride
OTHER: immunohistochemistry staining method
OTHER: laboratory biomarker analysis
PROCEDURE: biopsy

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]